Modality
Gene Editing
MOA
IL-17i
Target
CD38
Pathway
PI3K/AKT
Wilms
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
~Nov 2020
→ ~Feb 2022
Phase 2
May 2022
Phase 2Current
NCT04912450
2,613 pts·Wilms
2022-05→TBD·Recruiting
2,613 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P2/3
Recruit…
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04912450 | Phase 2/3 | Wilms | Recruiting | 2613 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 |